Try our Advanced Search for more refined results
Life Sciences
Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.
Sign up for a 7-day FREE trial today!
Latest News in Life Sciences
-
January 07, 2026
Kaplan Fox Remains Lead In Securities Suit After Ex-Client DQ
Kaplan Fox & Kilsheimer LLP will continue leading a putative securities class action against Spectrum Pharmaceuticals after a previously appointed lead plaintiff was removed from the case for allegedly going behind his lawyers' backs to push his own settlement plan and unrelated conspiracy theories.
-
January 07, 2026
Detroit Pension Fund Wins 'Close' Call To Lead Investor Suit
A Detroit pension fund should lead a proposed shareholder class action against MoonLake Immunotherapeutics, though a competing bid by a France-based lab worker and screenwriter alleges a "marginally larger" investment loss, a Manhattan federal judge has determined.
-
January 06, 2026
Bayer Targets Pfizer, Moderna, J&J For Covid Jab Royalties
Bayer wants a cut of the profits Johnson & Johnson, Moderna, Pfizer and BioNTech have reaped from sales of their COVID-19 vaccines, which the German biotech company alleges were only made possible through infringement of its intellectual property, according to lawsuits filed Tuesday in New Jersey and Delaware federal courts.
-
January 06, 2026
Cigna Accused Of Rigging Market For Life-Saving Drugs
Patients with chronic health conditions sued Cigna in an Illinois federal court alleging in a proposed class action Tuesday that the company and its pharmacy and pharmacy benefit manager subsidiaries use exclusive agreements to lock users into a network where Byzantine refill processes have been deliberately erected to limit payouts for life-saving drugs.
-
January 06, 2026
FDA To Ease Regulation Of Wearables, Decision Software
U.S. Food and Drug Administration Commissioner Marty Makary touted new federal guidance on Tuesday that he said would promote innovation by making it easier to bring certain kinds of wearable devices and clinical-decision software to market without a strict regulatory review.
Areas of Coverage
- AGENCIES
- U.S. Consumer Product Safety Commission
- U.S. Food and Drug Administration
- U.S. Patent and Trademark Office
- U.S. International Trade Commission
- POLICY & REGULATION
- Affordable Care Act
- Federal Food, Drug, and Cosmetic Act
- Antitrust and consumer protection controls
- Drug and medical device lobbying
- State and international life sciences legislation and regulation
- ENFORCEMENT
- Drug and medical device recalls
- Drug safety actions
- Pay-for-delay investigations
- Merger reviews
- LITIGATION
- Patent disputes, including
- Abbreviated New Drug Application litigation
- Section 301 cases
- Product safety suits over drugs and medical devices, including off-label marketing and failure-to-warn claims
- Consumer litigation and class actions
- Fraud and compliance suits
- Antitrust disputes
- Labor and employment suits
- Shareholder and corporate governance disputes
- Bankruptcy proceedings
- TRANSACTIONS
- Mergers, acquisitions, and joint ventures
- Share buybacks and stock splits
- Private equity deals
- Patent-licensing agreements
- PROFILES
- Personnel moves
- Profiles of life sciences practice groups
Readership
- Life sciences lawyers at top law firms
- Corporate counsel and compliance officers at Fortune 1000 companies
- Executives and attorneys in the drug, biotechnology, and medical device industries
- Information experts at law firms, agencies, and companies
- Policymakers at federal and state agencies
- Judges and court staff across the U.S.
- Professors, students, and library staff at every accredited law school in the U.S.
- Attorney and law firm marketing professionals